Aberrant forms of Escherichia coli in blood cultures: in vitro reproduction of an in vivo observation.
Aberrant filamentous forms of Escherichia coli were observed on direct Gram stain of blood cultures from a patient being treated with the beta-lactam antibiotic cephalexin. After the institution of an alternative antibiotic regimen which included a different cell wall-active agent, E. coli of normal morphology was detected in blood cultures for an additional 48 h. Filamentous forms of E. coli could be reproduced reliably in vitro by incubating the organism in Mueller-Hinton broth containing various concentrations of cephalexin. Both supra- and subinhibitory concentrations of cephalexin resulted in filament formation after 4 h of incubation, whereas 24 h of incubation yielded intact filaments at only a narrow range of subinhibitory concentrations of cephalexin. In vitro comparison of the ability of cephalexin, cephalothin, ampicillin, and gentamicin to cause filamentous forms of E. coli showed that cephalexin and cephalothin produced pure filament formation after 4 h of incubation at subinhibitory concentrations of as low as one-fourth the minimum inhibitory concentration of the antibiotic. Ampicillin was not associated with pure filament formation at concentrations below the minimum inhibitory concentration, and gentamicin produced no filaments at any concentration. The effect of preincubation of E. coli with subinhibitory concentrations of cephalexin on subsequent minimum inhibitory concentrations of ampicillin was examined in an effort to develop an explanation for the persistent sepsis exhibited by the patient. No diminution of the activity of ampicillin by preincubation with cephalexin could be demonstrated. Other possible clinical implications of filamentous forms of gram-negative bacilli are discussed.
D000667:Ampicillin / Q000494:pharmacology; D002506:Cephalexin / Q000494:pharmacology* / Q000627:therapeutic use; D002512:Cephalothin / Q000494:pharmacology; D004926:Escherichia coli / Q000166:cytology* / Q000187:drug effects; D004927:Escherichia coli Infections / Q000382:microbiology*; D005839:Gentamicins / Q000494:pharmacology; D006801:Humans; D008297:Male; D008875:Middle Aged; D018805:Sepsis / Q000382:microbiology*
D005839:Gentamicins; D000667:Ampicillin; D002506:Cephalexin; D002512:Cephalothin